Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Thalidomide in autoimmune conditions

References to Primarv Literature

• BURLEY D, DENNISON T, HARRISON W: Clinical experi-ence with a new sedative drug. The Practitioner (1959) 183:57–61.
   PubMedGoogle Scholar
• KUNZ W, KELLER H, MUECKTER N: N-phflialyl-glu-tamisaure-itnid (N-phthalyl-glutarnic Inside). Arzneim. Forsch. Drug Res. (1956) 6:426–430.
   PubMedGoogle Scholar
• WEIDENBACH A: Totale phokomelie. Zentralbl. f Gynak.(1959) 81:2048–2052.
   PubMedGoogle Scholar
• MCBRIDE W: Thalidomide and congenital abnormalities[Letter]. Lancet (1961) 2:1358.
   Web of Science ®Google Scholar
• LENZ W: Thalidomide and congenital abnormalities[Letter]. Lancet (1962) 1:45.
   Web of Science ®Google Scholar
• HASTINGS R: Kellersberg Memorial Lecture 1979. Immu-nosuppressive/anti-inflammatory thalidomide ana-logues. Ethiop. Med. J. (1980) 18:65–71.
   PubMedGoogle Scholar
• HASTINGS R: Studies on the Mechanisms of Action of Tha-lidomide in Inflammation. Dissertation, Tulane University (1971).
   Google Scholar
• STEPHENS T: Proposed mechanisms of action in thnlido-mide embryopathy. Teratology (1988) 38:229-239. A useful summary of many of the putative mechanisms of terato-genesis.
   Google Scholar
• GASPARINI G, HARRIS A: Clinical importance of the determination of tumour angiogenesis in breast carci-noma: much more than a new prognostic tooL J. Clin. Oncol. (1995) 13(3):765-782. Although this review article concentrates on breast carcinoma it summarises the current literature on the mechanisms, and evaluation of angiogenesis, and current anti-angiogenic agents.
   Google Scholar
• D'AMATO R, LOUGHNAN M, EVELYN F, FOLKMAN J: •Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91(9):4082–4085. The original observation of the anti-angiogenic potential of thalido-mide.
   Google Scholar
• GRABSTALD H, GOLBEY R: Clinical experience with thalidomide in patients with cancer. Clin. Pharmacol. Ther. (1965) 6(3):298–302.
   PubMed Web of Science ®Google Scholar
• OLSON K, HALL T, HORTON J, KHUNG C, HOSLEY H:Thalidomide (N-phthaloylglutatnimide) in the treat-ment of advanced cancer. Clin. Pharmacol. Ther. (1965) 6(3):292–297.
   PubMed Web of Science ®Google Scholar
• POLLARD M: Thalidomide promotes metastasis of pros-tate adenocarcinoma cells (Pa-Iii) in L-W rats. Cancer Lett. (1996) 101(1):21–24.
   PubMed Web of Science ®Google Scholar
• LANSING M, DLXIT S, GLASER B: The effect of systemic thalidomide and amiloride on neovascularization in the rabbit corneal micropoc.ket [Abstract]. J. Ophthalmol. Visual Sci. (1996) 37(3):S658.
   Google Scholar
• SAMPAIO E, AL MOREIRA, SARNO E, MALTA A, KAPLAN G:Prolonged treatment with recombinant interferon-y induces erythema nodosum leprosum in lepromatous leprosy patients. J. Exp. Med. (1992) 175:1729–1737.
   PubMed Web of Science ®Google Scholar
• NEUBERT R, NOGUEIRA A, NEUBERT D: Thalidomide derivatives and the immune system. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch. Toxicol. (1993) 67:1–17.
   Google Scholar
• RANDALL T: Thalidomide back in the news, but in morefavourable circumstances. JAMA (1990) 263(11):1467–1468.
   PubMed Web of Science ®Google Scholar
• MELLIN G, KATZENSTEIN M: The saga of thalidomide (concluded). New Engl. J. Med. (1962) 267:1238-1244. This is mainly of historical interest, and concentrates on the terato-genicity of thalidomide.
   Google Scholar
• NEUBERT R, NEUBERT D: Peculiarities and possible mode of action of thalidomide. Drug toxicity in Embryonic Development. Kavlock, Daston (Eds.), Springer Verlag. Handbook of Experimental Pharmacology (1996). 124. This review covers the possible mechanisms of thalidomide's tem-togenic potential, and covers the clinical recognition and investiga-tion of the teratogenicity.
   Google Scholar
• scorr W, FRADKIN R, WILSON J: Non-confirmation of thalidomide induced teratogenesis in rats and mice. Teratology (1977) 16:333–336.
   PubMedGoogle Scholar
• FABRO S, SMITH R, WILLIAMS R: Toxicity and teratogenic-ity of optical isomers of thniirlomide. Nature (1967) 215:296.
   PubMed Web of Science ®Google Scholar
• KUSSENBERG E, SIMPSON J, STANTON J: Is thalidomide to blame? Br. Med. J. (1961) 1:291.
   Google Scholar
• FLORENCE A: Is thalidomide to blame? Br. Med. J. (1960) 2:1954.
   Google Scholar
• BURLEY D: Is thalidomide to blame? Br. Med. J. (1961)1:130.
   Google Scholar
• FULLERTON P, KREMER M: Neuropathy after intake of thalidomide (Distaval). Br. Med. J. (1961) 2:855-858. The most complete early study of the neuropathy of thalidomide in subjects given the drug as a sedative.
   Google Scholar
• NEUBERT R: Thalidomide. Exp. Clin. Neurotoxictty (1996).
   Google Scholar
• •In press. This is a comprehensive review of the literature on neurotoxicity in both man, and animal models, and the possible mechanisms behind the neurotoxicity.
   Google Scholar
• BUCKLE R: Blood pyruvic acid in thalidomide neuropathy. Br. Med. J. (1963) 11:687–689.
   Google Scholar
• SCHRODER J, GIBBELS E: Unmyelinated nerve fibers in senile nerves and in late thalidomide neuropathy: a quantitative electron microscopic study. Ada Neuropathol. (Berlin) (1977) 39:271–280.
   PubMed Web of Science ®Google Scholar
• SCHRODER J, MATTHIESEN T: Experimental thalidomide neuropathy: the morphological correlate of reduced conduction velocity. Ada Neuropathol. (Berlin) (1985) 65:285–292.
   PubMed Web of Science ®Google Scholar
• FULLERTON P, O'SULLIVAN D: Thalidomide neuropathy: a clinical electrophysiological and histological follow- up study. j.Neurol. Neurosurg. Psychiatr. (1968) 31:543-551. An important paper which particularly examines the electrophysi-ological changes associated with thalidomide, noting that slowing on the conduction velocity is a late feature.
   Google Scholar
• GARDNER-MEDWIN J, POWELL R: Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's dis-ease: the use of neurophysiological studies to detect thalidomide neuropathy. Ann. Rheum. Dis. (1994) 53(12):828–832.
   PubMed Web of Science ®Google Scholar
• HAAS D, MARASIGAN A: Neurological effects of glutethimide. J. Neurol. Neurosurg. Psychiatr. (1968) 31:561–564.
   PubMed Web of Science ®Google Scholar
• KOCH H: Thalidomide and congeners as anti-inflamma-tory agents. Frog. Med. Chem. (1985) 22:165–242.
   PubMedGoogle Scholar
• KAITIN K: Graft-versus-host disease. New Engl. J. Med.(1991) 325:357–358.
   PubMed Web of Science ®Google Scholar
• CENTRES FOR DISEASE CONTROL: 1993 revised classifi-cation system for HIV infection and expanded surveil-lance case definition for AIDS among adolescents and adults. MMWR (1992) 41(RR-17):1–19.
   Google Scholar
• WEINROTH S, PARENTI D, SIMON G: Mini review. Wastelag syndrome in AIDS: Pathophysiologic mechanismsand therapeutic approaches. Infect. Agents Dis. (1995) 4:76-94. This review summarises the mechanisms behind the wasting syn-drome of AIDS, and the current therapeutic possibilities, including thalidomide.
   Google Scholar
• DEZUBE B, PARDEE A, CHAPMAN B: Pentoxifylline de-creases tumour necrosis factor expression and serum triglycerides in people with AIDS. J. Acquit.. Immune Defic. Syndr. (1993) 6:787–794.
   PubMed Web of Science ®Google Scholar
• TRACEY K, CERAMI A: The role of cachectinitumournecrosis factor in AIDS. Cancer Cells (1989) 1:62–63.
   PubMed Web of Science ®Google Scholar
• MITCHIE H, SHERMAN M, SPRIGGS D et al.:. Chronic TNF Infusion causes anorexia but not accelerated nitrogen loss. Ann. Surg. (1989) 209:19–24.
   Google Scholar
• EVANS R, ARGILES J, WILLIAMSON D: Metabolic effects of tumour necrosis factor-alpha (cachectin) and inter-leukin -1. Clin. Sci. (1989) 77:357–364.
   PubMed Web of Science ®Google Scholar
• BREEN E, REZAI A, NAKAJIMA K: Infection with HIV is associated with elevated IL-6 levels and production. J. Immunol. (1990) 144:480–484.
   PubMed Web of Science ®Google Scholar
• DESTEFANO E, FRIEDMAN R, FRIEDMAN-KEIN A: Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and iymphadenopathy. J. Infect. Dis. (1982) 146:451–455.
   PubMed Web of Science ®Google Scholar
• SOMERS G: Pharmacological parameters of thalidomide (a-phthalhnido giutarimide) a new sedative hypnotic drug. Br. J. Pharmacol. (1960) 15:111–116.
   PubMed Web of Science ®Google Scholar
• HARRIS S, ALLGOOD J: Analgesia enhancing effect of thalidomide. Proc. Soc. Exp. Biol. Med. (1960) 103:580–581.
   PubMed Web of Science ®Google Scholar
• MILLER J, GINSBERG M, MCELFATRICK G, SHONBERG I: The anti-inflammatory effect and analgesic property of contergan 268. Anti biot. Med. Clin. Ther. (1960) 7:743–746.
   Google Scholar
• ZWINGENBERGERK, WNENDT S:Immunomodulation by thalidomide. J. Infiamm. (1996). In press. A comprehensive review of the immunomodulatory effects of tha-lidomide, and possible mechanisms behind these.
   Google Scholar
• SIMPSON J: Mixed oedema after thalidomide (Distaval). Br. Med. J. (1962) 1:55.
   Google Scholar
• SFIESKIN J: Thalidomide lathe treatment of lepra reactions. Clin. Pharmacol. Ther. (1965) 6:303-306. The original observation of the therapeutic value of thalidomide in the lepra reaction.
   Google Scholar
• SHESKIN J: Further observations with thalidomide in lepra reactions. Lepr. Rev. (1965) 36:183–187.
   PubMedGoogle Scholar
• SHESKIN J: Therapeutische Erfa Hrungen uber den Ein-fluss des Thalidomids bei der Lepra-Reaktion. flaularzt (1975) 26:1–5.
   Google Scholar
• MASCARO J, LECHA M, TORRAS H: Thalidomide in the treatment of recurrent necrotic and giant mucocutane-ous aphthae and aphthosis. Arch. Dermatol. (1979) 115:636-637. The original observation of the therapeutic value of thalidomide in the oral and genital ulceration.
   Google Scholar
• TORRAS H, LECHA M, MASCARAO J: Thalidomide treat-ment of recurrent necrotic giant mucocutaneous aphthae and aphthosis. Arch. Dermatol. (1982) 118:704.
   Google Scholar
• SAYLAN T, SALTIK I: Thalidomide in the treatment of Behcet's syndrome. Arch. Dermatol. (1982) 118:536.
   PubMed Web of Science ®Google Scholar
• LONDONO F: Thalidomide in the treatment of actinic prurigo. Intl. Dermatol. (1973) 12:326–328.
   PubMedGoogle Scholar
• CARMICHAEL A, KNIGHT A: Thalidomide: a restricted role. Lancet (1992) 339:1362.
   PubMedGoogle Scholar
• KNOP J, BONSMANN G, HAPPLE R et al.: Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br. J. Dermatol. (1983) 108:461–466.
   PubMed Web of Science ®Google Scholar
• SAMSOEN M, GROSSHANS E, BASSET A: La thalidomide darn le traitemertt du lupus erythemateux chronigue. Ann. Dermatol. Venereol. (1980) 107:515–523.
   PubMedGoogle Scholar
• BURROWS N, WALPORT M, HAMMOND A, DAVEY N, JONES RR: Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide. Br . J . Dermatol. (1991) 125:62–67.
   PubMed Web of Science ®Google Scholar
• SHESKIN J: The treatment of lepra reaction in leproma-tons lepra: Fifteen years' experience with thalidomide. Int. J. Dermatol. (1980) 19:318–322.
   PubMed Web of Science ®Google Scholar
• WULFF C, HOYER H, ASBOE-HANSEN G, BRODTHAGEN H: Development of polyneuropathy during thalidomide therapy. Br. J. Dermatol. (1985) 112:475–480.
   PubMed Web of Science ®Google Scholar
• CLEMMENSEN O, OLSEN PZ, ANDERSEN K: Thalidomide neurotoxicity. Arch. Dermatol. (1984) 120:338–341.
   PubMed Web of Science ®Google Scholar
• WATERS M, LAING A, AMBIKAPATHY A, LENNARD-JONES J: Treatment of ulcerative colitis with thalidomide. Br. Med. J. (1979) 123:792.
   Google Scholar
• BAKMER F, ZAUR H, LUSZPINSKI P: Thalidomide treat-ment of recurrent erythema multiforine. Acta Dermatol. Venereol. (1982) 62:449.
   PubMed Web of Science ®Google Scholar
• LAUGIER P, HUNZLKER N, HARMS M, BADER C, CHAVAZ P: Case demonstrations at the Geneva University Der-matology Clinic. Dermatologica (1982) 165(4):271–278.
   PubMedGoogle Scholar
• COCK KD: Treatment of ulcerative colitis. Br. Med. J. (1979) 1:1356.
   PubMed Web of Science ®Google Scholar
• BARNHILL R, MCDOUGALL A: Thalidomide: use and pos-sible mode of action in reactional lepromatous leprosy and in various other conditions. J. Am. Acad. Derrnatol. (1982) 7:317–323.
   PubMed Web of Science ®Google Scholar
• ERAVELLY J, WATERS M: Thalidomide in Weber-Chris-tian disease. Lancet (1977) 1:251.
   PubMed Web of Science ®Google Scholar
• VOGELSANG G, HESS A, GORDON G, SANTOS G: Treat-ment and prevention of acute graft-versus-host disease with thalidomide in a rat modeL Transplantation (1986) 41:644–664.
   Google Scholar
• VOGELSANG G, FARMER E, HESS A et al.: Thalidomide for the treatment of chronic graft-versus-host disease. New EngL J. Med. (1992) 326:1055–1058.
   Google Scholar
• AUSTYN J, WOOD K: Cytokines mediating inflammatory, and effector functions. Principles of Cellular and Molecu-lar Immunology. Austyn JMW, KJ. (Ed.), Oxford University Press, Oxford (1993).
   Google Scholar
• HENEY D, NORFOLK D, WHEELDON J et al.: Thalidomide treatment for chronic graft-versus-host disease. Br. J. Haematol. (1991) 78: 23–27.
   PubMed Web of Science ®Google Scholar
• HENEY D, BAILEY C, LEWIS I: Thalidomide in the treat-ment of graft-versus-host disease. Biomed. Pharma-cother. (1990) 44:199–204.
   PubMed Web of Science ®Google Scholar
• HENEY D, LEWIS I, BAILEY C: Thalidomide for chronic graft-versus-host disease in children. Lancet (1988) 2:1317.
   PubMed Web of Science ®Google Scholar
• YOULE M, CLABOUR J, FARTHING C et al.: Treatment ofresistant aphthous ulceration with thalidomide in pa-tients positive for HIV antibody. Br. Med. J. (1989) 298:432.
   PubMed Web of Science ®Google Scholar
• RYAN J, COLEMAN J, PEDERSEN J, BENSON E: Thalido-mide to treat esophageal ulcers in AIDS. New Engl.J. Med. (1992) 327(3):208–209.
   PubMedGoogle Scholar
• RADEFF B, KUFFER R, SAMSON J: Recurrent aphthous ulcer in patient infected with Human Immunodefi-ciency Virus: successful treatment with thalidomide. J. Am. Acad. Dermatol. (1990) 23:523–525.
   PubMed Web of Science ®Google Scholar
• GHIGLOTTI G, REPETTO T, FARIS A, ROY M, DEMARCH R: Thalidomide for severe apthous ulceration in patients with human immunodefidency virus (1IV) infection. Am.]. Gastroenterol. (1993) 89(12):2276–2277.
   Google Scholar
• NAUM S, MOLLOY P, KANIA R, MCGARR J, THIEL DV: Use of thalidomide in treatment and maintenance of idi-opathic esophageal ulcers in HIV+ individuals. Dig. Dis. Sci. (1995) 40(5):1147–1148.
   PubMed Web of Science ®Google Scholar
• HILLMAN R, GOLDMEIER D, TAYLOR-ROBINSON D: Scro-tal ulceration in HIV-positive patients. Genitourin. Med. (1990) 66:93–94.
   PubMedGoogle Scholar
• STRAZZI S, LEBBE C, GEOGGRAY C et al.: Aphthous ulceration in HIV-infected patients: treatment with tha-lidomide. Genitourin. Med. (1992) 68:424–425.
   PubMedGoogle Scholar
• HELLMAN K, DUKE D, TUCKER D: Prolongation of skinhomograft survival by thalidomide. Br. Med. J. (1965) 2:687–689.
   PubMed Web of Science ®Google Scholar
• TURK J, HELLMANN K, DUKE D: Effect of thalidomide on the immunological response in local lymph nodes after a skin homograft. Lancet (1966) 1:1134.
   PubMed Web of Science ®Google Scholar
• FIELD E, GIBBS J, TUCKER D, HELLMANN K: Effect of thalidomide on the graft versus host reaction. Nature (1966) 211:1308–1310.
   PubMed Web of Science ®Google Scholar
• FLOERSHEIM G: Another chance for thalidomide. Lancet(1966) 1:207.
   PubMed Web of Science ®Google Scholar
• PLAYFAIR J, LEUCHARS E, DAVIES A: Effect of thalidomideon skin-graft survival. Lancet (1963) 1:1003–1004.
   Web of Science ®Google Scholar
• LEVI S, MCWHANNELL A, VORA A, BOUGHTON B: Success-ful treatment with thalidomide of acute graft-versus-host-disease after bone marrow transplantation. Lancet (1988) 1:117.
   Web of Science ®Google Scholar
• MCCARTHY D, KANFER J, TAYLOR E, BARRETT A: Thalido-mide for graft-versus-host disease. Lancet (1988) 2:1135.
   PubMed Web of Science ®Google Scholar
• MCCARTHY D, KANFER J, BARRETT A: Thalidomide for the therapy of graft-versus-host disease following allo-geneic bone marrow transplantation. Biomed. Pharma-cother. (1989) 43:693–697.
   PubMed Web of Science ®Google Scholar
• PARKER P, CHAO N, NADEMANEE A et al.: Thalidomide as salvage therapy for chronic graft-versus-host-dis-ease. Blood (1995) 86(9):3604–3609. A large trial of thalidomide in chronic graft-versus-host-disease, where thalidomide is used following other treatment failure. A high incidence of reversible side-effects leading to treatment withdrawal occured. A 20% sustained response to thalidomide was noted.
   Google Scholar
• JADHAV V, PAKTI A, MEHTA J: Thalidomide in type-2lepra reaction: a clinical experience. Indian J Lepr. (1990) 62:316–320.
   PubMedGoogle Scholar
• IYER C, LANGUILLON J, RAMANUJUM K et al.: WHO co-ordinates short term double-blind trial with thalido-mide in the treatment of acute lepra reactions in male lepromatous patients. Bulletin of the World Health Organ-isation (1971) 45:719–732.
   PubMed Web of Science ®Google Scholar
• JAKEMAN P, SMITH W: Thalidomide in the leprosy reac-tion. Lancet (1994) 343:432–433.
   PubMed Web of Science ®Google Scholar
• CRAWFORD C: Use of thalidomide in leprosy [Letter]. Br.Med.]. (1991) 302:1603–1604.
   PubMed Web of Science ®Google Scholar
• MCKERROW R: First Tuesday. Yorkshire Television (1993).
   Google Scholar
• PARIDA S, GRAU G, ZAHEER S, MUKHERJEE R: Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions. Clin. Immunol. Immunopathol. (1992) 63(1):23–27,
   PubMedGoogle Scholar
• SARNO E, GRAU G, VIEIRA L, NERY J: Serum levels oftumour necrosis factor-alpha and interleuldn-1 beta during leprosy reactional states. Clin. Exp. Immunol. (1991) 84(1):103–108.
   PubMedGoogle Scholar
• SAMPAIO E, KAPLAN G, MIRANDA A et al.: The influenceof thalidomide on the clinical and immunologic mani-festations of erythema nodosum leprosum. J. Infect. Dis. (1993) 168(2):408–414.
   Google Scholar
• BHATTACHARYA S, CHATTOPADHAYA D, SAHA K: Tu-mor necrosis factor: status in reactions in leprosy before and after treatment. Int. J. Dermatol. (1993) 32(6):436–439.
   PubMed Web of Science ®Google Scholar
• SAGHER F: Thalidomide neuropathy. Lepr. Rev. (1969)40(2):126–130.
   Google Scholar
• LEHNER T, BARNES C: Criteria for diagnosis and classi-fication of Behcet's syndrome. In: Behcet's Syndrome: Clinical and Immunological Features. Lehner T, Barnes C (Eds.), Academic Press, London (1979).
   Google Scholar
• HONMA T, MORIOKA D: Electron microscopic study on the pathogenesis of recurrent aphthous ulceration as compared to Behcet's syndrome. Oral Surg. (1976) 41(3):366–377.
   Google Scholar
• LARSSON H: Case report treatment of severe colitis in Behcet's syndrome with thalidomide (CG-217)../. Intern. Med. (1990) 228:405–407,
   PubMed Web of Science ®Google Scholar
• REVUZ J, GUILLAUME J, JANIER M et at.: Crossover study of thalidomide vs. placebo in severe recurrent aphthous stomatitis. Arch. Dermatol. (1990) 126:923–927.
   Google Scholar
• POWELL R, ALLEN B, JENKINS J et at,: Investigation and treatment of orogenital ulceration; studies on a possible mode of action of thalidomide. Br. J. Dermatol. (1985) 113(28)141–144.
   Google Scholar
• BARR C, TOROSIAN J: Oral manifestations in patients with AIDS or AIDS-related complex. Lancet (1986) 2:288.
   PubMed Web of Science ®Google Scholar
• VERBERKMOES A, BOER K, WERTHEIM P, BRONKHORST C, LANGE J. Thalidomide for genital ulcers in HIV-posi-tive woman [Letter]. Lancet (1996) 347:974.
   PubMedGoogle Scholar
• PATERSON D, GEORGHIOU P, ALLWORTH A, ICEMPR: Thalidomide as treatment of refractory apthous ulceration related to human immunodeficiency virus infection. Cfin. Infect. Dis. (1995) 20:250-254. A retrospective review of treatment with thalidomide of refractory apthous ulcers in HIV, including oral, esophageal and rectal ulcera-tion, which demonstrated an impressive response to moderate doses of thalidomide.
   Google Scholar
• WILLIAMS I, WELLER I, MALIN A, ANDERSON J, WATERS M: Thalidomide hypersensitivity in AIDS. Lancet (1991) 337:436–437.
   PubMed Web of Science ®Google Scholar
• LAILDEVIRTA J, MAURY C, TEPPO A, REPO H: Elevated levels of circulating cachecthiltumour necrosis factor In patients with acquired immunodeficiency syn-drome. Am.J. Med. (1988) 85:289–291.
   PubMed Web of Science ®Google Scholar
• BEUTLER B, GREENWALD D, HULMES J: Identity of tu-mour necrosis factor and the macrophage secreting cachectin. Nature (1985) 316:552–554.
   PubMed Web of Science ®Google Scholar
• BOGDEN J, BAKER H, FRANK O: Micronutrient status and human immunodeficiency virus (HIV) infection. Ann. NY Acad. Sci. (1990) 587:189–195.
   PubMed Web of Science ®Google Scholar
• REDDY M, SORREL S, LANGE M, GRIECO M: Tumour necrosis factor and HIV p24 antigen in the serum of HIV-infected population. J. AIDS (1988) 1:436–440.
   PubMed Web of Science ®Google Scholar
• GRUNFIELD C, KOTLER D, HAMADEH R et at.: Hyper-triglyceridemia in the acquired immunodeficiency syn-drome. Am. J. Med. (1989) 86:27–31.
   Google Scholar
• GRUNFIELD C, KOTLER D: Wasting in the acquired im-munodeficiency syndrome. Semin. Liver Dis. (1992) 12:175–187.
   PubMed Web of Science ®Google Scholar
• GRUNFIELD C, PANG M, SHIMIZU L et al.: Resting energy expenditure, calorie intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am. J. Clin. Nutr. (1992) 55:455–460.
   PubMed Web of Science ®Google Scholar
• SAMPAIO E, SARNO E, GALILLY R, COHN Z, KAPLAN G: Thalidomide selectively inhibits tumour necrosis factor a production by stimulated human monocytes. J. Exp. Med. (1991) 173:699–703.
   PubMed Web of Science ®Google Scholar
• MAKONKAWKEYOON S, LIMSON-PROBRE R, MORIERA A, SCHAUF V, KAPLAN G: Thalidomide inhibits the replica-tion of human imanunodeficiency virus type 1. Proc. Natl. Acad. Set. USA (1993) 90(13):5974–5978.
   PubMed Web of Science ®Google Scholar
• REYES-TERAN G, SIERRA-MADERO J, CERRO VMD: Effects of thalidomide on wasting syndrome in patients with AIDS: a randomised, double-blind placebo controlled clinical trial. Tenth International Conference on AIDS (1994):65.
   Google Scholar
• KLAUSNERJ, MAKONKAWKEYOON S, AKARASEWI P et at.: The effect of thalidomide on the pathogenesis of Hu-man Immunodeficiency Virus Type 1 and Mycobac-terium tuberculosis infection. J. Acquir. Immunodefic. Syndr. Human Retrovirol. (1996) 11(3):247–257.
   Google Scholar
• DEZUBE B: Pentoxifylline for the treatment of infection with human immunodeficiency virus. din. Infect. Dis. (1994) 18:285–287.
   Web of Science ®Google Scholar
• SHARPSTONE D, ROWBOTTOM A, SMITH N, GAZZARD B: The treatment of microsporidiosis with thalidomide. AIDS (1995) 9(6):658–659.
   PubMed Web of Science ®Google Scholar
• KOTLER D, ORENSTEIN J: Small intestinal injury and parasitic infection in AIDS. Ann. Intern. Med. (1984) 113:444–449.
   Google Scholar
• BESSIS D, GUILLOT B, MONPOINT S, DANDURA_ND M, GUILHOU J: Thalidomide for systemic lupus erythema-tosus. Lancet (1992) 339:549–550.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ-RODRIGUEZ O: Thalidomide: a promising new treatment for rheumatoid arthritis. Arthritis Rheum. (1984) 27:1118–1121.
   PubMed Web of Science ®Google Scholar
• SCOVILLE C: Open trial of thalidomide in the treatment of rheumatoid arthritis [Abstract]. Arthritis Rheum. (1995) 38(9):769.
   Web of Science ®Google Scholar
• RIFKIN I, MCHUGH S, BRADLEY J et at.: Thalidomide as treatment for refractory systemic vasculitis: possible mechanism of action. Kidney Int. (1995) 47(2):672.
   Google Scholar
• SHESKIN J: Zur Therapie der Prurigo Nodularis Hyde mit Thalidomid. Hautarzt (1975) 26:215–217.
   PubMedGoogle Scholar
• DOMINGUEZ L, HOJYO M: Actinic prurigo, a variety of polymorphous light eruption. Int. J. Dermatol. (1982) 21(5):260–261.
   PubMed Web of Science ®Google Scholar
• MOISSON Y, JANIER M, CIVA'rTE J: Thalidomide for recurrent erythema multiforme. Br. J. Dermatol. (1992) 126(1):92–93.
   PubMed Web of Science ®Google Scholar
• BUCKLEY C, BAYOUMI A, SARKANY I: Pyoderma gan-grenosum with severe pharyngeal ulceration. J. Royal Soc. Med. (1990) 83:590–591.
   PubMed Web of Science ®Google Scholar
• MUNRO C, COX N: Pyoderma gangrenosum associated with Behcet's syndrome-response to thalidomide. din. Exp. Dermatol. (1988) 13:408–410.
   PubMed Web of Science ®Google Scholar
• POWELL F, SCHROETER A, SU WD, PERRY H: Pyoderma gangrenosum and monoclonal gammopathy. Arch. Der-matol. (1983) 119:468–472.
   Google Scholar
• CARLESIMO M, GIUSTINI S, ROSSI A, BONACCORSI P, CALVIERI S:0 Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J. Am. Acad. Dermatol. (1995) 32(5 Part 2):866–869.
   Google Scholar
• THOMAS L, DUCROS B, SECCHI T, BALME B, MOULIN G: Successful treatment of adult's Langerhans cell histio-cytosis with thalidomide. Arch Dermatol. (19 9 3) 129:1261-1264.
   Google Scholar
• MISERY L, LARBRE B, LYONNET S, FAURE M, THIVOLET J: Remission of Langerhans cell histiocytosis with tha-lidomide treatment. Clin. Exp. Dermatol. (1993) 18(5):487.
   PubMed Web of Science ®Google Scholar
• MEUNIER L, MARCK Y, RIBEYRE C, MEYNADIER J: Adult cutaneous Langerhans cell histiocytosis: remission with thalidomide treatment. Br. J. Dermatol. (1995) 132(1):168.
   PubMed Web of Science ®Google Scholar
• HMSO: The Medicine Act. HMSO, London (1968).
   Google Scholar
• POWELL R, GARDNER-MEDWIN J: Guideline for the clini- cal use and dispensing of thalidomide. Postgrad. Med. J.(1994) 70(830):901–904. Important for those considering using thalidomide to ensure it is used as safely as possible.
   Google Scholar
• CHAUDHRY V, CORNBLATH D, MELLITIS E et al.: Inter-and I/Ara-examiner reliability of nerve conduction measurements in normal subjects. Ann. Neurol. (1991) 30:841–843.
   PubMed Web of Science ®Google Scholar
• BLEASEL A, TUCK R: Variability of repeated nerve con-duction studies. Electroenceph. Clin. Neurophys. (1991) 81:417–420.
   PubMedGoogle Scholar
• LAMMER E, CHEN D, HOAR R: Retinoic acid em-bryopathy. New Engl, J. Med. (1985) 313:837–841.
   PubMed Web of Science ®Google Scholar